Comparison between Y90 Radioembolization Plus Sorafenib and Y90 Radioembolization alone in the Treatment of Hepatocellular Carcinoma: A Propensity Score Analysis
Background: Adjuvant sorafenib may enhance the efficacy of transarterial radioembolization with yttrium-90 in hepatocellular carcinoma patients. The aim of this study is to assess the efficacy and safety of radioembolization plus sorafenib in comparison to radioembolization alone. Methods: Out of 17...
Main Authors: | Antonio Facciorusso, Irene Bargellini, Marina Cela, Ivan Cincione, Rodolfo Sacco |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-04-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/12/4/897 |
Similar Items
-
Sarcopenia Worsening One Month after Transarterial Radioembolization Predicts Progressive Disease in Patients with Advanced Hepatocellular Carcinoma
by: Giulio Eugenio Vallati, et al.
Published: (2021-07-01) -
Radioembolization for the treatment of hepatocellular carcinoma
by: Hyo-Cheol Kim
Published: (2017-06-01) -
Yttrium-90 radioembolization in patients with hepatocellular carcinoma who have previously received sorafenib
by: Nitesh eRana, et al.
Published: (2013-12-01) -
History and Evolution of Yttrium-90 Radioembolization for Hepatocellular Carcinoma
by: Aman Saini, et al.
Published: (2019-01-01) -
Radioembolization versus chemoembolization for unresectable hepatocellular carcinoma: a meta-analysis of randomized trials
by: Casadei Gardini A, et al.
Published: (2018-10-01)